<2023>

[9] Biomarkers for determining immune status in colorectal cancer patients and used thereof

Lee IS, Kim HS, Choi IS, Kim KA

​

<2022>

[8] Exosome derived biomarker for diagnosing colorectal cancer and uses thereof (10-2022-0133986)

Kim HS, Kim KA, Seo Y, Han YD

PCT/WO 2022/010919 A2

​

<2021>

[7] Peptides of bacteriophage for selective targeting of Fusobacterium Nucleatum and composition comprising the same (10-2021-0133821)

Kim HS, Kim KA, Ahn JB, Paik SM, Yong DE, Lee HM

Very appreciative of Dr. Kim KA's contribution to the patent! Congratulations!

​

<2020>

[6] Exosomal tumor biomarkers and collections thereof

Lyden D, Hoshino A, Bojmar L, Kim HS

U.S. Provisional Patent Application Serial No. 63/048,406 (filed July 6, 2020)

U.S. Provisional Patent Application Serial No. 63/064,825 (filed Aug 12, 2020)

​

<2019>

[5] Methods for providing information of mortality risk and devices for providing information of mortality risk using the same (No. 10-2310888)

Kim HS, Park JH, Oh SW, Shin M, Ko RE

​

<2018>

[4] Guide RNA complementary to KRAS gene and use thereof (No. 10-1997116)

Kim HH, Kim WJ, Kim HS

USA: 16/341, 585

PCT/KR2017/011391

<2016>

[3] Method of identifying neoantigens and device for identifying neoantigens using same (No. 10-1918818)

Kim SW, Kim SR, Kim HS

[2] A programmable nuclease targeting hepatitis B virus and a composition for treating HBV infection comprising the same (No. 10-1842131)

Kim HH, Lee MG, RAMUGOPALAPPA, Kim YH, Kim HS

​

<2014>

[1] Predictive biomarkers for EGFR tyrosine kinase inhibitors as anticancer therapy (No. 10-1622454)
Cho BC, Kim HS

PCT/KR2016/002064